Welcome to our dedicated page for Century Therapeutics news (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.
Century Therapeutics, Inc. (NASDAQ: IPSC) is a biotechnology company at the forefront of advancing cell therapies for cancer and autoimmune diseases. Utilizing adult stem cells, specifically induced pluripotent stem cells (iPSCs), Century Therapeutics leverages its proprietary Allo-Evasion™ technology to develop curative therapies that overcome the limitations of first-generation cell therapies.
The company's innovative platform integrates several advanced technologies including CRISPR-mediated gene editing, proprietary chimeric antigen receptors (CARs), and cutting-edge manufacturing capabilities. These combined elements enhance cell product performance, prevent host immune system rejection, and minimize development risks, positioning Century Therapeutics as a leader in the biotech sector.
Key Candidates and Achievements
- CNTY-101: An investigational CD19-targeting iPSC-derived natural killer (NK) cell therapy, CNTY-101 is designed for treating relapsed or refractory non-Hodgkin lymphoma (NHL). This product incorporates six precision gene edits and has shown promising early response signals, including complete and partial responses in clinical trials.
- Allo-Evasion™ Technology: Core to Century's strategy, this technology enables repeat dosing without the need for continual lymphodepletion, significantly improving patient outcomes. The company presented comprehensive data demonstrating the protective capabilities of its Allo-Evasion™ edits at major scientific conferences.
- Dual-Targeting CARs: Century has developed a novel CD19xCD22 bispecific CAR, demonstrating effective cytotoxicity against tumors in preclinical models, further expanding the potential applications of its therapies.
Recent News and Developments
- Clinical Trial Success: The ELiPSE-1 Phase 1 trial showcased encouraging initial data for CNTY-101, revealing its potential in treating aggressive B-cell lymphomas.
- New Partnerships and Acquisitions: The acquisition of Clade Therapeutics, a leader in iPSC-derived αβ T cells, enhances Century's pipeline, technology, and expertise in the cell therapy space.
- Financial Growth: Century recently secured $60 million in private placement funding, underscoring investor confidence in its strategic direction and potential market impact.
- Research Expansion: The company is expanding its clinical development into autoimmune disease indications, with a focus on leveraging its iPSC platform to address significant unmet medical needs.
For more detailed information about Century Therapeutics and its groundbreaking work in cell therapy, visit www.centurytx.com.
Century Therapeutics (NASDAQ: IPSC) announced that it will present preclinical data from its iPSC-based cell therapy platform at the Society for Immunotherapy of Cancer's 37th Annual Meeting, scheduled for November 8-12, 2022, in Boston. The company will showcase two poster presentations: one focusing on enhancing iNK cell therapies for better anti-tumor efficacy on November 10, and the other on targeting solid tumors with iPSC-derived CAR T cells on November 11. These advancements underline the company's commitment to innovative cancer therapies.
Century Therapeutics (NASDAQ: IPSC) appointed Daphne Quimi and Timothy Walbert to its Board of Directors as part of a strategic move to enhance its leadership. Quimi, currently CFO of Amicus Therapeutics, brings extensive experience in finance and accounting, while Walbert, CEO of Horizon Therapeutics, adds expertise in product commercialization. The announcement also disclosed the resignation of Eli Casdin from the Board, effective October 1, 2022. These changes aim to accelerate the company's development of innovative cell therapies for cancer treatment.
Century Therapeutics (NASDAQ: IPSC) announced CEO Lalo Flores will join the panel discussion on “Next Generation Gene Editing” at Chardan’s 6th Annual Genetic Medicines Conference on October 3, 2022, at 10:30 AM ET. This participation highlights the company's focus on developing iPSC-derived cell therapies for cancer treatment. A live webcast of the event will be available on their website, with a replay archived for a limited time.
Century Therapeutics (NASDAQ: IPSC) announced that Chief Operations Officer Adrienne Farid, Ph.D., will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 9:00 AM ET. The event will be available via live webcast on the company's website, with an archive for later viewing. Century is focused on developing cell therapies for cancer using induced pluripotent stem cells, aiming to improve patient access to innovative treatments. The company emphasizes its expertise in genetic engineering and cellular reprogramming to overcome challenges in the current cell therapy landscape.
Century Therapeutics has received FDA clearance for its CNTY-101 investigational new drug application, targeting relapsed or refractory CD19-positive B-cell malignancies. This marks a significant milestone for the company, which aims to advance the allogeneic cell therapy space with CNTY-101, engineered with six gene edits, Allo-Evasion™ technology, IL-15 support, and a safety switch. The Phase 1 ELiPSE-1 trial is expected to begin in the second half of 2022, assessing the drug's safety and efficacy following conditioning chemotherapy.
Century Therapeutics (NASDAQ: IPSC) reported its Q2 2022 results, ending June 30 with $429.4M in cash. The company is set to initiate the Phase 1 ELiPSE-1 trial for CNTY-101, pending FDA clearance, targeting relapsed/refractory CD19 positive lymphoma. Collaboration revenue stood at $1.4M, while R&D expenses rose to $24.5M due to expanded capabilities. General and administrative costs increased to $8.3M, leading to a net loss of $31M. The company forecasts 2022 operating expenses between $155M and $165M, with a cash runway extending into 2025.
Century Therapeutics (NASDAQ: IPSC) will join the Russell Microcap Index effective June 27, 2022, following the Russell indexes annual reconstitution. This membership lasts one year and includes automatic inclusion in corresponding growth and value style indexes. The Russell indexes are utilized by investment managers and institutional investors, with approximately $12 trillion in assets benchmarked against them. Century Therapeutics focuses on developing iPSC-derived cell therapies for cancer treatment, aiming to overcome limitations of existing therapies.
Century Therapeutics (NASDAQ: IPSC) will have its CEO, Lalo Flores, Ph.D., participate in a fireside chat at the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 28, 2022, at 9:30 AM ET. The event will discuss the company's innovative work in induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology. Interested parties can access a live webcast on the company’s website, with a replay available for 30 days.
Century Therapeutics (NASDAQ: IPSC) announced a virtual Research and Development Day on June 13, 2022, from 4:30 PM to 6:00 PM ET. The event will showcase presentations from the management team and Dr. Sheila Singh, focusing on next-generation iPSC-derived cell therapy technologies, particularly in treating glioblastoma with CNTY-103. This event aims to highlight the company's advancements in immuno-oncology and its innovative approach to addressing cancer therapies.
Century Therapeutics (NASDAQ: IPSC) reported its Q1 2022 financial results, highlighting a cash position of $466.4 million and a net cash provided by operations of $86.8 million. The company plans to initiate its Phase 1 ELiPSE-1 trial for CNTY-101 in relapsed/refractory lymphoma in H2 2022 after IND submission. R&D expenses increased to $21.2 million, driven by expanded headcount and studies. The net loss stood at $37.5 million. The company expects its financial resources to sustain operations through 2025.
FAQ
What is the current stock price of Century Therapeutics (IPSC)?
What is the market cap of Century Therapeutics (IPSC)?
What is Century Therapeutics' primary focus?
What is CNTY-101?
How does Century Therapeutics' Allo-Evasion™ technology work?
What recent achievements has Century Therapeutics made?
What are the potential applications of Century's dual-targeting CARs?
What are Century Therapeutics' plans for autoimmune diseases?
How does Century Therapeutics ensure the safety of its cell therapies?
What financial milestones has Century Therapeutics recently achieved?
Where can I find more information about Century Therapeutics?
What partnerships does Century Therapeutics have?
